{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:13:46Z","timestamp":1788362026257,"version":"build-2803163510"},"reference-count":90,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Capecitabine-induced hand-foot syndrome (HFS) is a frequent and clinically relevant toxicity that may impair quality of life and lead to chemotherapy dose reduction or interruption. This study aimed to evaluate the effectiveness, safety, and clinical predictors of response to topical recombinant human epidermal growth factor (rhEGF) gel combined with urea ointment in patients with capecitabine-induced HFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective case series included a total of 83 patients with colorectal adenocarcinoma who developed Grade II\u2013III capecitabine-induced HFS and received topical rhEGF gel plus urea ointment between January 2022 and December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 61 years, and 49 patients (59.0%) were male. At baseline, 48 patients (57.8%) had Grade II HFS and 35 (42.2%) had Grade III HFS. After 3 weeks of treatment, 67 patients (80.7%) achieved at least a one-grade reduction in HFS severity. The median HFS grade significantly decreased after treatment (Wilcoxon, signed-rank, p\u2009&lt;\u20090.001), with no cases of worsening. Improvements were observed in pain (70\/70 affected patients; 100.0%), erythema (73\/76; 96.1%), desquamation (60\/60; 100.0%), and ulceration (18\/24; 75.0% among affected patients). The median time to first documented improvement was 10 days. In an exploratory adjusted model, early treatment initiation within 7 days was associated with higher odds of response, whereas baseline Grade III HFS was associated with lower odds of response. No serious adverse events considered related to treatment were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Topical rhEGF gel plus urea ointment was associated with rapid, well-tolerated improvement in capecitabine-induced HFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261475247","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:32:25Z","timestamp":1788190345000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical Recombinant Human Epidermal Growth Factor (rhEGF) gel plus urea ointment in the management of capecitabine-induced hand-foot syndrome: A case series with literature review"],"prefix":"10.1177","author":[{"given":"Jianjun","family":"Zhou","sequence":"first","affiliation":[{"name":"The Third Affiliated Hospital of Wenzhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Chen","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Wenzhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deen","family":"Shi","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Wenzhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Wenzhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"1390","article-title":"Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation","volume":"16","author":"de Queiroz MVR","year":"2022","unstructured":"de Queiroz MVR, de Medeiros A, Toledo SP, et al. Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation. Ecancermedicalscience 2022; 16: 1390.","journal-title":"Ecancermedicalscience"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06319-2"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114232"},{"key":"e_1_3_4_5_2","first-page":"45","article-title":"Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia","volume":"32","author":"King TL","year":"2024","unstructured":"King TL, Voon PJ, Yuen KH, et al. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia. Support Care Cancer 2024; 32: 45.","journal-title":"Support Care Cancer"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-012-0057-0"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00004"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1706"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2020.442"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S13238"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01730"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04794-5"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S517489"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.14187"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13377"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2025.102326"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13653"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998332692241202072249"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010883"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00611-y"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13740"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.42"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20240517"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13822"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116102"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0009"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1038-y"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10198-y"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13684-1"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01730"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00638"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v14.i4.364"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238583"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-025-01119-9"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8739473"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2013.0473"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-06036-6"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2014.0540"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14046720"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2009.00622.x"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","unstructured":"Nanes BA Bhatt K Boujemaa-Paterski R et al. Keratin isoform shifts modulate motility signals during wound healing. bioRxiv. 2024. doi: 10.1101\/2023.05.04.538989.","DOI":"10.1101\/2023.05.04.538989"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759091415602463"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2014.0561"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2019.05.041"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13377"},{"key":"e_1_3_4_47_2","first-page":"186","article-title":"A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D\u2122 150) in healing diabetic foot ulcers","volume":"18","author":"Viswanathan PS","year":"2006","unstructured":"Viswanathan PS, Sekar N, Murthy GSR. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D\u2122 150) in healing diabetic foot ulcers. Wounds 2006; 18: 186\u2013196.","journal-title":"Wounds"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.06.004"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sap.0000198731.12407.0c"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12187"},{"key":"e_1_3_4_51_2","unstructured":"Wang SL Ma JL Chai JK. [Acceleration of burn wound healing with topical application of recombinant human epidermal growth factor ointments]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2002;16(3):173\u20136."},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkac002"},{"key":"e_1_3_4_53_2","article-title":"Growth factors for treating diabetic foot ulcers","volume":"2015","author":"Mart\u00ed-Carvajal AJ","year":"2015","unstructured":"Mart\u00ed-Carvajal AJ, Gluud C, Nicola S, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev 2015; 2015: Cd008548.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2009.0750"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475x.2000.00162.x"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.14075"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1856"},{"key":"e_1_3_4_58_2","first-page":"5365","article-title":"Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds","volume":"15","author":"Xu J","year":"2018","unstructured":"Xu J, Min D, Guo G, et al. Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds. Exp Ther Med 2018; 15: 5365\u20135370.","journal-title":"Exp Ther Med"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2021.33.6.549"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12969"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01260-4"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4587"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr400"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701184"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23478.x"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.133"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13575"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.26442\/20751753.2025.6.203306"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1335551"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060505"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1694066"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142067"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1694066"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200910040-00006"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12196"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12877"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_175_21"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.06.026"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13568"},{"key":"e_1_3_4_80_2","first-page":"718725","article-title":"Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis","volume":"2012","author":"Bernard FX","year":"2012","unstructured":"Bernard FX, Morel F, Camus M, et al. Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis. J Allergy (Cairo) 2012; 2012: 718725.","journal-title":"J Allergy (Cairo)"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228790"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.11.006"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113120"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41038-019-0148-1"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105054"},{"key":"e_1_3_4_87_2","doi-asserted-by":"crossref","unstructured":"Lod\u00e9n M. Urea As a Moisturizing and Barrier-Enhancing Ingredient. 2009. p. 335\u201346.","DOI":"10.3109\/9781420070958.021"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.4142\/jvs.2006.7.2.105"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202012073"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0698"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02857-4"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261475247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261475247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261475247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:24:12Z","timestamp":1788359052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261475247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":90,"alternative-id":["10.1177\/10781552261475247"],"URL":"https:\/\/doi.org\/10.1177\/10781552261475247","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"10781552261475247"}}